Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world phase IV study of deutetrabenazine in Chinese patients with Huntington's disease chorea
CTR20210393Phase 4Active
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of deutetrabenazine in Huntington disease (HD), tardive dyskinesia (TD), sponsored by Teva Pharmaceutical Industries Ltd.. Started Feb 2024; status: active.
02
Drugs
deutetrabenazine
03
Conditions
Huntington disease (HD)tardive dyskinesia (TD)
Beyond the preview
Go deeper on CTR20210393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210393.